Agency
Winter Haven Hospital INC
Winter Haven Hospital INC was paid $26.30M by Medicaid between Jan 2018 and Dec 2024, across 294 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoWINTER HAVEN HOSPITAL INC
WINTER HAVEN, FL 33881
WINTER HAVEN, FL 33881
33aNPI1477599975assigned 06/22/2006
33bProvider typeCase Management Agency
28Total paid$26.30M
24GClaims1,088,606
24DCodes billed294
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Case Management Agency providers in Florida
Rank by total paid#6 of 357
Median peer was paid$839K
This provider vs. median31×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 73,363 | $656K | |
| 2019 | 225,170 | $4.66M | |
| 2020 | 204,986 | $4.42M | |
| 2021 | 205,625 | $4.69M | |
| 2022 | 191,554 | $5.45M | |
| 2023 | 126,047 | $4.01M | |
| 2024incomplete | 61,861 | $2.41M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 41,606 | 36,397 | $3.75M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.3% | 37,454 | 32,223 | $2.44M |
| H2019 | Therapeutic behavioral services, billed per 15 minutesTherapeutic behavioral services, per 15 minutes | 7.3% | 41,853 | 30,083 | $1.93M |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 7.3% | 39,718 | 31,708 | $1.91M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.3% | 21,363 | 17,118 | $1.40M |
| 80053 | Comprehensive metabolic panel | 5.2% | 55,409 | 41,923 | $1.36M |
| H0032 | Mental health service plan development by non-physician | 3.3% | 20,494 | 16,641 | $858K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 9,760 | 8,345 | $832K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 5,289 | 4,653 | $718K |
| 76819 | Fetal biophysical profile; without non-stress testing | 2.5% | 16,752 | 10,729 | $670K |
| T1017 | Case management, billed per 15 minutesTargeted case management, each 15 minutes | 2.3% | 10,614 | 2,158 | $595K |
| 59899 | 2.0% | 5,988 | 3,860 | $536K |
282 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 7,524 | $527K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.9% | 13,283 | $508K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 7,850 | $460K |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 1.7% | 2,123 | $443K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.5% | 5,313 | $387K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.5% | 8,548 | $385K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 2,935 | $371K |
| H0031 | Mental health assessment, by non-physician | 1.4% | 9,507 | $363K |
| H2000 | Comprehensive multidisciplinary evaluation | 1.2% | 2,206 | $326K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.0% | 3,447 | $273K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 6,318 | $260K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 5,038 | $251K |
| 59410 | <1% | 291 | $235K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,965 | $210K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 10,210 | $204K |
| G0378 | Hospital observation service, per hour | <1% | 19,790 | $189K |
| 81003 | <1% | 36,700 | $175K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 64,339 | $169K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,210 | $160K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,384 | $157K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 8,162 | $150K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 791 | $143K |
| 84112 | <1% | 643 | $130K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,109 | $118K |
| 81025 | <1% | 12,488 | $117K | |
| 87631 | <1% | 2,434 | $113K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,051 | $107K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,921 | $100K |
| 82948 | <1% | 21,915 | $97K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 269 | $75K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,069 | $70K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,164 | $65K |
| 96367 | <1% | 999 | $65K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,918 | $62K |
| 71045 | Radiologic examination, chest; single view | <1% | 23,445 | $58K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,801 | $55K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,577 | $53K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,925 | $53K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,020 | $51K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 282 | $51K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 66,331 | $50K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 927 | $49K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,589 | $49K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,726 | $47K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,969 | $44K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 660 | $44K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,848 | $44K |
| 59025 | Fetal non-stress test | <1% | 1,549 | $39K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 771 | $38K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 964 | $38K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 876 | $35K |
| 99443 | <1% | 1,020 | $35K | |
| 87480 | <1% | 2,356 | $34K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,934 | $30K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,442 | $24K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,504 | $23K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,430 | $22K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,121 | $22K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 615 | $21K |
| A9270 | Non-covered item or service | <1% | 4,787 | $20K |
| 97161 | <1% | 522 | $20K | |
| 84702 | <1% | 4,296 | $20K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 26,051 | $19K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 197 | $19K |
| 99442 | <1% | 1,065 | $19K | |
| 76821 | <1% | 3,491 | $19K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,751 | $17K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,887 | $16K |
| 85610 | <1% | 12,889 | $15K | |
| 84484 | <1% | 22,685 | $15K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,407 | $15K |
| 73610 | <1% | 983 | $14K | |
| 76801 | <1% | 2,474 | $14K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,060 | $14K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,170 | $14K |
| 93971 | <1% | 1,257 | $14K | |
| 73630 | <1% | 1,137 | $13K | |
| 73130 | <1% | 880 | $13K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,190 | $13K |
| 83735 | <1% | 10,987 | $13K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 180 | $12K |
| 73030 | <1% | 1,411 | $12K | |
| 74022 | <1% | 782 | $12K | |
| 74018 | <1% | 834 | $12K | |
| C1769 | Guide wire | <1% | 970 | $11K |
| 76820 | <1% | 2,948 | $11K | |
| 80061 | Lipid panel | <1% | 6,168 | $11K |
| 86850 | <1% | 2,740 | $11K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,203 | $10K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,862 | $10K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,743 | $10K |
| 59515 | <1% | 14 | $10K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,099 | $9K |
| 83880 | <1% | 7,271 | $9K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,599 | $9K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 524 | $9K |
| 72100 | <1% | 1,671 | $9K | |
| 93017 | <1% | 466 | $8K | |
| 36591 | <1% | 963 | $8K | |
| 87070 | <1% | 706 | $8K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,943 | $8K |
| 97162 | <1% | 115 | $8K | |
| 86900 | <1% | 4,385 | $8K | |
| 97035 | <1% | 1,501 | $7K | |
| 72131 | <1% | 126 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,240 | $7K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,338 | $7K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,134 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,475 | $7K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 351 | $6K |
| 93970 | <1% | 460 | $6K | |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | <1% | 266 | $6K |
| 85027 | <1% | 7,785 | $6K | |
| 85730 | <1% | 6,059 | $6K | |
| J3490 | Unclassified drugs | <1% | 1,019 | $6K |
| 73562 | <1% | 455 | $6K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,323 | $6K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 88 | $5K |
| 84156 | <1% | 882 | $5K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,156 | $5K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,858 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,044 | $5K |
| 84481 | <1% | 264 | $5K | |
| 86780 | <1% | 1,041 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 122 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,555 | $4K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 295 | $4K |
| 73110 | <1% | 459 | $4K | |
| 87340 | <1% | 1,669 | $4K | |
| 0100U | <1% | 115 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,174 | $4K |
| 87077 | <1% | 3,547 | $3K | |
| 84100 | <1% | 1,824 | $3K | |
| 0352U | <1% | 136 | $3K | |
| 84703 | <1% | 4,290 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,946 | $3K |
| 83690 | <1% | 11,351 | $3K | |
| 87040 | <1% | 1,719 | $3K | |
| 54150 | <1% | 45 | $3K | |
| 70486 | <1% | 77 | $3K | |
| 96156 | <1% | 1,030 | $3K | |
| 82550 | <1% | 3,732 | $3K | |
| 83605 | <1% | 3,015 | $2K | |
| 70491 | <1% | 15 | $2K | |
| 87186 | <1% | 2,862 | $2K | |
| 73502 | <1% | 364 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 109 | $2K |
| 12001 | <1% | 209 | $2K | |
| 96376 | <1% | 245 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 3,557 | $2K |
| 84145 | <1% | 2,178 | $2K | |
| 97602 | <1% | 18 | $2K | |
| 11043 | <1% | 68 | $2K | |
| 76770 | <1% | 64 | $2K | |
| 85380 | <1% | 2,606 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 920 | $2K |
| 86901 | <1% | 4,339 | $2K | |
| 73564 | <1% | 140 | $2K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 373 | $2K |
| 81001 | <1% | 1,103 | $2K | |
| 82728 | <1% | 1,435 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,206 | $2K |
| 80074 | <1% | 150 | $2K | |
| 82607 | <1% | 1,051 | $2K | |
| 86803 | <1% | 632 | $2K | |
| 87641 | <1% | 292 | $2K | |
| 84550 | <1% | 297 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 161 | $1K |
| 36416 | <1% | 295 | $1K | |
| 87205 | <1% | 926 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,452 | $974.06 |
| 85018 | <1% | 1,591 | $955.69 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 1,283 | $952.83 |
| 73590 | <1% | 81 | $889.18 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,434 | $814.87 |
| 93880 | <1% | 137 | $804.56 | |
| 82805 | <1% | 158 | $784.87 | |
| 82950 | <1% | 284 | $774.94 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 82 | $759.03 |
| 82247 | <1% | 406 | $755.27 | |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 49 | $750.13 |
| 84439 | <1% | 1,754 | $739.66 | |
| 94760 | <1% | 417 | $729.65 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 21 | $716.51 |
| 86592 | <1% | 343 | $690.61 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 169 | $682.33 |
| 83655 | <1% | 167 | $617.92 | |
| 73560 | <1% | 155 | $604.02 | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 284 | $593.39 |
| 99205 | Prolong outpt/office vis | <1% | 30 | $590.54 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 743 | $562.20 |
| 90714 | <1% | 661 | $545.11 | |
| 12011 | <1% | 71 | $539.52 | |
| 12002 | <1% | 69 | $531.26 | |
| 73090 | <1% | 46 | $510.72 | |
| 82140 | <1% | 186 | $489.41 | |
| T1023 | Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter | <1% | 37 | $467.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,322 | $454.01 |
| 85652 | <1% | 1,592 | $428.30 | |
| 87660 | <1% | 2,416 | $427.66 | |
| 72040 | <1% | 89 | $420.36 | |
| 86140 | <1% | 2,138 | $375.97 | |
| 83540 | <1% | 945 | $318.64 | |
| 87510 | <1% | 2,354 | $318.07 | |
| 87081 | <1% | 201 | $312.36 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 288 | $290.27 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 13 | $288.72 |
| 86762 | <1% | 657 | $255.98 | |
| 29125 | <1% | 98 | $226.18 | |
| 82746 | <1% | 489 | $224.73 | |
| 97032 | <1% | 258 | $201.09 | |
| 83550 | <1% | 640 | $194.18 | |
| 93976 | <1% | 14 | $191.29 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 16 | $167.16 |
| 84436 | <1% | 219 | $163.64 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 37 | $153.01 |
| 84144 | <1% | 34 | $150.99 | |
| 83020 | <1% | 247 | $149.40 | |
| 83021 | <1% | 247 | $117.28 | |
| 87075 | <1% | 106 | $115.81 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 22 | $111.56 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 131 | $104.09 |
| 82248 | <1% | 605 | $101.53 | |
| 87581 | <1% | 114 | $90.05 | |
| 87486 | <1% | 114 | $90.05 | |
| 82947 | <1% | 380 | $84.56 | |
| 84450 | <1% | 272 | $80.20 | |
| 80164 | <1% | 50 | $79.57 | |
| 83615 | <1% | 808 | $78.44 | |
| 0240U | <1% | 164 | $74.46 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 1,628 | $69.27 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 17 | $69.00 |
| 86787 | <1% | 261 | $67.36 | |
| 84460 | <1% | 273 | $65.63 | |
| 85045 | <1% | 41 | $63.32 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 17 | $56.05 |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 1,377 | $52.82 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 135 | $46.18 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 368 | $37.27 |
| 90686 | <1% | 58 | $32.31 | |
| 82570 | <1% | 853 | $29.18 | |
| 87640 | <1% | 44 | $27.81 | |
| 82043 | <1% | 252 | $23.55 | |
| 87430 | <1% | 69 | $23.49 | |
| 82150 | <1% | 91 | $22.89 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 933 | $18.85 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 738 | $16.53 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 617 | $11.02 |
| 82077 | <1% | 1,025 | $7.78 | |
| 85014 | <1% | 68 | $5.68 | |
| 84480 | <1% | 16 | $4.57 | |
| 84132 | <1% | 34 | $3.10 | |
| 72170 | 0% | 83 | $0.00 | |
| 71101 | 0% | 29 | $0.00 | |
| 96150 | 0% | 24 | $0.00 | |
| 0399T | 0% | 104 | $0.00 | |
| 96151 | 0% | 113 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 102 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 194 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 17 | $0.00 |
| 85379 | 0% | 70 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 14 | $0.00 |
| 96415 | 0% | 17 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 46 | $0.00 |
| 86376 | 0% | 31 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 20 | $0.00 |
| 73552 | 0% | 13 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 96 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 33 | $0.00 |
| 82010 | 0% | 423 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 31 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 227 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 108 | $0.00 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 18 | $0.00 |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 0% | 17 | $0.00 |
| 86003 | 0% | 21 | $0.00 | |
| 76376 | 0% | 181 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 36 | $0.00 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 0% | 14 | $0.00 |
| 0353U | 0% | 84 | $0.00 | |
| 93356 | 0% | 83 | $0.00 | |
| 82465 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCUBERO, TAMBLYN (MANAGER, CBO FINANCE)
| Provider | Location | Paid |
|---|---|---|
| ST Josephs Diagnostic Center LLC | Tampa, FL | $54K |
| ST. Anthony's Professional Buildings & Services, INC | St Petersburg, FL | $21K |
| Morton Plant Mease Health Services INC | Clearwater, FL | $15K |
| Morton Plant Mease Health Services, INC | Clearwater, FL | $11K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.